Troy Lister is Vice President of Research and Development at Spero Therapeutics in Cambridge, Massachusetts.
Before joining Spero Therapeutics in 2014, Troy was previously team leader of infection chemistry at AstraZeneca and Investigator III in Global Discovery Chemistry at the Novartis Institute for BioMedical Research (NIBR). He has led numerous discovery programmes searching for novel agents to target bacterial and viral pathogens including both Gram-negative and Gram-positive multidrug-resistant bacteria as well as other pathogens such as respiratory syncytial virus and Ebola virus.
He has also led programmes from the earliest stages of target selection and high-throughput screening. Other programmes he has led have focused on lead identification and optimization, candidate selection, first in human (FIH) enablement and early clinical development.
Troy received his Bachelor of Science degree as well as his PhD in Chemistry from Flinders University, Australia and was a postdoctoral fellow with Prof. K. C. Nicolaou at The Scripps Research Institute in La Jolla, USA.